• Radiation Oncology Journal
• /
• 제26권1호
• /
• pp.10-16
• /
• 2008

목적: 조기 유방암에서 유방보존치료와 유방절제술의 치료 성적을 비교하고, 예후 인자를 알아보고자 하였다. 대상 및 방법: 1994년 9월부터 2002년 12월까지 본원에서 근치적 수술을 받은 병리학적 병기 $T1{\sim}2N0$ 유방암 환자 1,200명을 후향적으로 분석하여 유방보존치료와 유방절제술을 사이의 차이를 비교해 보았다. 결과: 분석에 포함된 1,174명의 환자 중 601명이(51.2%) 유방보존치료를 받았고 573명이(48.8%) 유방절제술을 받았다. 유방절제술을 받은 군에서 유의하게 종양의 크기가 컸고, 다발성(multicentricity), 에스트로겐 및 프로게스테론 수용체 음성 등의 인자가 더 많은 경향을 보였다. 유방보존치료 및 유방절제술을 받은 환자의 10년 생존율은 각각 91.96%와 91.01%였고(p=0.1274), 10년 무병생존율은 각각 80.48%와 84.95%(p=0.8795)로 유의한 차이를 보이지 않았다. 결론: 조기 유방암에서 유방보존치료 내지는 유방절제술을 받은 군 사이에 환자 특성의 차이는 일부 있었으나 생존율에서 유의한 차이를 보이지 않았다.

• Radiation Oncology Journal
• /
• 제32권2호
• /
• pp.84-94
• /
• 2014

Purpose: To quantify the cardiac dose reduction during breathing adapted radiotherapy using Real-time Position Management (RPM) system in the treatment of left-sided breast cancer. Materials and Methods: Twenty-two patients with left-sided breast cancer underwent CT scans during breathing maneuvers including free breathing (FB), deep inspiration breath-hold (DIBH), and end inspiration breath-hold (EIBH). The RPM system was used to monitor respiratory motion, and the in-house self respiration monitoring (SRM) system was used for visual feedback. For each scan, treatment plans were generated and dosimetric parameters from DIBH and EIBH plans were compared to those of FB plans. Results: All patients completed CT scans with different breathing maneuvers. When compared with FB plans, DIBH plans demonstrated significant reductions in irradiated heart volume and the heart $V_{25}$, with the relative reduction of 71% and 70%, respectively (p < 0.001). EIBH plans also resulted in significantly smaller irradiated heart volume and lower heart $V_{25}$ than FB plans, with the relative reduction of 39% and 37%, respectively (p = 0.002). Despite of significant expansion of lung volume using inspiration breath-hold, there were no significant differences in left lung $V_{25}$ among the three plans. Conclusion: In comparison with FB, both DIBH and EIBH plans demonstrated a significant reduction of radiation dose to the heart. In the training course, SRM system was useful and effective in terms of positional reproducibility and patient compliance.

• Radiation Oncology Journal
• /
• 제35권4호
• /
• pp.325-331
• /
• 2017

Purpose: There is controversy regarding the cosmetic outcome after accelerated partial breast radiation (APBR). We report the cosmetic outcome from a single-arm prospective clinical trial of APBR delivered using intensity-modulated radiation therapy (IMRT) in elderly patients with stage I breast cancer (BC), using a novel fractionation schedule. Materials and Methods: Forty-two patients aged ${\geq}65$, with Stage I BC who underwent breast-conserving surgery were enrolled in a phase I/II study evaluating a 2-week course of APBR. Thirty eligible patients received 40 Gy in 4 Gy daily fractions. Cosmetic outcome was assessed subjectively by physician/patient and objectively by using a computer program (BCCT.core) before APBR, during, and after completion of the treatment. Results: The median age was 72 years, the median tumor size was 0.8 cm, and the median follow-up was 50.5 months. The 5-year locoregional control in this cohort was 97% and overall survival 87%. At the last follow-up, patients and physicians rated cosmesis as 'excellent' or 'good' in 100% and 91 %, respectively. The BCCT.core program scored the cosmesis as 'excellent' or 'good' in 87% of the patients at baseline and 81% at the last follow-up. The median $V_{50}$ (20 Gy) of the whole breast volume (WBV) was 37.2%, with the median WBV $V_{100}$ (40 Gy) of 10.9%. Conclusion: An excellent rate of tumor control was observed in this prospective trial. By using multiple assessment techniques, we are showing acceptable cosmesis, supporting the use of IMRT planned APBR with daily schedule in elderly patients with early stage BC.

• 대한방사선치료학회지
• /
• 제22권1호
• /
• pp.41-46
• /
• 2010

목 적: 유방암의 접선조사 시 쐐기필터를 이용한 Conventional RT 기법과 정적다엽조리개를 이용한 FiF-IMRT 기법을 이용하여 전산화 치료계획 시 발생하는 선량분포의 차이를 환자의 유방 크기와 형태에 따라 분류하여 비교 분석하고자 한다. 대상 및 방법: 유방암 환자 30명을 대상으로 Eclipse treatment planning system ($Varian^{TM}$, USA, V8.0)을 사용하여 전산화 치료 계획을 시행하여 유방의 크기와 형태에 따라 분류하고, Dose Volume Histogram (DVH)을 이용하여 Conformity Index (CI)와 Homogeneity Index (HI)를 비교 분석하였다. 결 과: CI값은 ${\pm}1.2%$의 차이를 나타냈으며 FiF-IMRT의 경우 Conventional RT보다 HI값이 평균 1.67% 낮은 값으로 유방의 크기와 형태에 따른 분류값과 ${\Delta}HI$ (%)값의 상관관계를 알아본 결과 단면길이와 부피에서 높은 상관관계를 보였으며 통계적으로 유의(P<0.01)하였다. 결 론: 유방의 단면 길이와 부피가 증가할수록 Conventional RT의 경우보다 FiF-IMRT로 전산화 치료계획 시 유방 내의 선량 균등성이 향상되었으며 유방의 크기에 따라 그 효과가 다르므로 유방의 크기에 따른 적절한 치료계획이 필요할 것으로 생각된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권5호
• /
• pp.1683-1686
• /
• 2015

Different types of treatment are available for patients with breast cancer, the most being radiotherapy, chemotherapy, hormonal therapy and combination therapy. Recently, nanoparticles have been emerging as promising agents for cancer therapy and are being investigated as contrast agents, drug carriers, radiosensitizers and also for hyperthermia effects. In this review the focus is on approaches for targeted treatment of breast cancer by combining nanoparticles, chemodrugs and radiation. The availble data suggest the possibility of increased roles for combined therapy, particularly by reducing the dose of each treatment modality, and consequently minimizing related side effects.

• Journal of Magnetics
• /
• 제21권1호
• /
• pp.133-140
• /
• 2016

In this study the contralateral breast skin dose was decreased. It was to apply the results to the clinical study after analysis of different radiation dose amounts to contralateral breast with nonmagnetic bolus and without nonmagnetic bolus. A Rando phantom was computed tomography (CT) simulated, five treatment plans were generated: open tangents, open field in field, wedge 15, wedge 30, and intensity-modulated radiotherapy (IMRT) plan with 50.4 Gy to cover sufficient breast tissue. Contralateral breast skin dose was measured at 8 points using a glass dosimeter. The average contralateral breast dose using nonmagnetic bolus showed better excellence in decreasing the absorbed dose in the order of $168{\pm}11.1$ cGy, $131{\pm}10.2$ cGy (29%), $112{\pm}9.7$ cGy (49%), and $102{\pm}9.5$ cGy (64%) than changing the treatment plan. This study focused on decreasing the effect of scattered dose by use of a nonmagnetic bolus on the contralateral breast during radiotherapy in breast cancer patients and an intriguingly significant decrease was observed parallel to the opposed beam.

• Journal of Radiation Protection and Research
• /
• 제48권2호
• /
• pp.100-106
• /
• 2023

Background: As breast tissue expanders consist of metallic materials in the needle guard and ferromagnetic injection port, irradiation can produce radioactivation. Materials and Methods: A CPX4 (Mentor Worldwide LLD) breast tissue expander was exposed using the Versa HD (Elekta) linear accelerator. Two photon energies of 6 and 10 MV-flattening filter free (FFF) beams with 5,000 monitor units (MU) were irradiated to identify the types of radiation. Furthermore, 300 MU with 10 MV-FFF beam was exposed to the CPX4 breast tissue expander by varying the machine dose rates (MDRs) 600, 1,200, and 2,200 MU/min. To assess the instantaneous dose rates (IDRs) solely from the CPX4, a tissue expander was placed outside the treatment room after beam irradiation, and a portable radioisotope identification device was used to identify the types of radiation and measure IDR. Results and Discussion: After 5,000 MU delivery to the CPX4 breast tissue expander, the energy spectrum whose peak energy of 511 keV was found with 10 MV-FFF, while there was no resultant one with 6 MV-FFF. The time of each measurement was 1 minute, and the mean IDRs from the 10 MV-FFF were 0.407, 0.231, and 0.180 μSv/hr for the three successive measurements. Following 10 MV-FFF beam irradiation with 300 MU indicated around the background level from the first measurement regardless of MDRs. Conclusion: As each institute room entry time protocol varies according to the working hours and occupational doses, we suggest an addition of 1 minute from the institutes' own room entry time protocol in patients with CPX4 tissue expander and the case of radiotherapy vaults equipped with a maximum energy of 10 MV photon beams.

• Radiation Oncology Journal
• /
• 제28권3호
• /
• pp.177-183
• /
• 2010

목 적: 유방암 치료를 위한 방사선치료계획에 전산화단층촬영을 이용한 모의치료가 널리 이용되고 있다. 이는 환자 개개인의 해부학적 특징에 기반하여 종양 표적과 정상 조직을 정의할 수 있다. 본 연구는 일반적으로 유방 크기가 작은 한국인 유방암 환자에서 적용하는 방사선치료계획 방법에 따라 치료용적 및 치료범위에 차이가 있는지를 알아보기 위해 시행하였다. 대상 및 방법: 2008년 11월부터 2009년 1월까지 조기유방암으로 유방보존술을 시행 받은 25명의 환자를 대상으로 통상적인 접면조사의 이차원치료 계획과 전산화단층촬영을 기반으로 한 삼차원치료계획을 시행하였다. 이차원 치료계획에서 방사선조사영역의 경계는 유방실질을 촉지하여 결정하였고 위쪽으로는 쇄골의 바로 아래, 내측은 몸의 정중선, 외측은 중심 액와선 그리고 아래쪽은 유방밑주름에서 2 cm 아래에 표시하였다. 삼차원치료계획에서 임상표적체적은 모든 유선 조직을 포함하였고 계획용 표적체적은 임상표적체적에서 피부 쪽을 제외한 모든 방향으로 1 cm의 여유를 두어 결정하였다. 이차원과 삼차원치료계획 간의 조사영역의 경계 차이 및 동등조사영역의 차이를 확인하고 신체질량지수, 폐경 여부 및 유방크기의 관련성을 평가하였다. 그리고 선량분포로 지정한 유방조사량과 삼차원 선량분포에 기반하여 측정된 조사된 폐용적과 심장용적을 평가하였다. 결 과: 2명의 환자를 제외하고 계획용표적체적(PTV)은 삼차원치료계획이 이차원치료계획보다 모든 방향에서 표시한 방사선조사영역을 감소시켰고 위쪽 경계에서 그 차이값이 가장 컸다. 동등조사영역크기는 한 명을 제외하고 삼차원치료계획에서 이차원치료계획에서보다 작았으며(평균 0.9 cm), 신체질량지수, 폐경 여부 및 유방크기(브래지어 사이즈)와의 관련성은 보이지 않았다. 조사된 폐용적은 삼차원치료계획에서 유의하게 감소하였고, 심장용적 또한 감소하였지만 통계적으로 유의한 차이는 보이지 않았다. 결 론: 통상적인 치료계획과 비교하여 전산화단층촬영을 기반으로 한 삼차원치료계획이 작은 유방을 가진 환자에서 방사선조사영역 및 손상위험장기의 조사량을 줄이면서 수술 후 변화를 포함하여 더 정확한 종양치료가 가능할 수 있음을 보여주었다. 그러나 앞으로 임상표적체적의 정의에 대한 추가적인 연구 및 일반적인 합의가 필요하다.

• 종양간호연구
• /
• 제3권1호
• /
• pp.5-14
• /
• 2003

The purpose of this study was to identify key educational and counseling needs of breast cancer patients in Korea. The data were collected from 102 breast cancer survivors. The instrument consisted of 66 items and the items were divided into five treatment stages: pre-admission, admission, discharge, chemotherapy, and radiation therapy. The subjects' mean age was 50 years and most of them were housewives. All had a mastectomy and among them 69 had chemotherapy and 42 had radiation therapy. Average post-surgical period was 47 months. The mean score of the subjects' needs was 2.99 out of 4 points. The highest educational need was to know about the method of recurrence prevention. In terms of the treatment stages, mean score for pre-admission was 3.09, admission 3.06, chemotherapy 3.03, after discharge 2.95, and radiation therapy 2.80. In the pre-admission period, etiology, diagnostic tests, treatment and prevention of the breast cancer were needed the most. During the admission period, symptom management after the operation had the highest score. After discharge, prevention of recurrence had the highest score. The results of this research will help in developing educational and counseling programs by understanding the specific needs of breast cancer patients based on the treatment stages.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권15호
• /
• pp.6359-6364
• /
• 2015

Background: Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)- positive cell lines enhance antitumor efficacy. This retrospective analysis of a group of patients with metastatic breast cancer (MBC) evaluated the efficacy and safety of combined AI with capecitabine. Materials and Methods: Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy. Results: Of 72 patients evaluated, 31 received the combination treatment, 22 AI and 19 capecitabine. The combination was used in 20 patients as first-line and 11 as second-line treatment. Mean age was 46.2 years with a range of 28-72 years. At the time of progression, 97% had a performance status of <2 and 55% had visceral disease. No significant difference was observed between the three groups according to clinical and pathological features. Mean follow up was 38 months with a range of 16-66 months. The median PFS of first-line treatment was significantly better for the combination (PFS 21 months vs 8.0 months for capecitabine and 15.0 months for AI). For second-line treatment, the PFS was longer in the combination compared with capecitabine and Al groups (18 months vs. 5.0 months vs. 11.0 months, respectively). Median 2 year and 5 year survival did not show any significant differences among combination and monotherapy groups. The most common adverse events for the combination group were grade 1 and 2 hand-for syndrome (69%), grade 1 fatigue (64%) and grade 1 diarrhoea (29%). Three grade 3 hand-foot syndrome events were reported. Conclusions: Combination treatment with capecitabine and AI used as a first line or second line treatment was safe with much lowered toxicity. Prospective randomized clinical trials should evaluate the use of combination therapy in advanced breast cancer to confirm these findings.